Aktiesnakken — November 2009
-
must match headcount
-
en anelse underligt at der på forsiden af genmab.com linkes til "view a tour of our manufacturing facility"....
-
en sidste tribute... ellelr måske til interesserede købere...
-
fabrikken skulle sikre nok kapacitet, men portfolio review har gjort behovet mindre, og de kan få det leveret udefra
-
egfr skal stadig produceres til lonza
-
kun 38 mill dkk effekt i cash på 2009
-
nu egfr
-
we remain highly optimistic
-
hun sagde takeover!!!
-
hun skulle sige stakeholder!
-
ELLER også var det bare mig
-
hun vil godt levere shareholdervalue - jo tak
-
3 spørgsmål fra Piper
-
Er der kontrakt med Lonza for kommerciel produktion af EGFR
-
scaleup work for egfr er completed
-
david eatwell nu. annualized savings 300 mill. 240 cash impact.
-
broadly speaking så kan man trække 300 mill ud, men dog med 1q 2010 der screwer lidt med folk der stadig er tilbage
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind